Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -393.4%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $31M | $234M | $16M | $29M | $62M | $430M | — | — |
| Enterprise Value | $44M | $246M | $1M | $31M | $41M | $397M | — | — |
| P/E Ratio → | -0.37 | — | — | — | — | — | — | — |
| P/S Ratio | 1421.88 | 10628.51 | — | 14.81 | 18.86 | 187.89 | — | — |
| P/B Ratio | 40.63 | 41.84 | 0.63 | 0.44 | 0.49 | 7.13 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11195.38 | — | 15.69 | 12.61 | 173.35 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -16431.8% | -16431.8% | — | 100.0% | 100.0% | 100.0% | 100.0% | -16987.1% |
| Operating Margin | -289668.2% | -289668.2% | — | -4687.9% | -1889.3% | -1765.4% | -6267.5% | -25625.9% |
| Net Profit Margin | -279263.6% | -279263.6% | — | -3592.4% | -1771.5% | -2414.6% | -5041.1% | -24890.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -393.4% | -393.4% | -114.1% | -73.2% | -62.0% | -6652.9% | — | -117.8% |
| ROA | -82.4% | -82.4% | -48.6% | -47.3% | -42.0% | -76.3% | -47.2% | -59.0% |
| ROIC | -328.8% | -328.8% | -114.9% | -79.3% | -69.6% | — | — | — |
| ROCE | -104.5% | -104.5% | -63.7% | -68.8% | -50.7% | -64.4% | -65.8% | -69.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.17 | 5.17 | 1.31 | 0.56 | 0.29 | 0.38 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.23 | -0.57 | 0.03 | -0.16 | -0.55 | — | -0.30 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 | 6.52 | 4.36 |
| Quick Ratio | 1.67 | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 | 6.52 | 4.36 |
| Cash Ratio | 1.18 | 1.18 | 3.67 | 2.84 | 5.46 | 3.85 | 6.28 | 4.14 |
| Asset Turnover | — | 0.00 | — | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 5358.86 | — | 3266.92 | 69.53 | 76.95 | 293.67 | 334.94 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $225M | $5M | $4M | $4M | $4M | $4M | $1M |
Imminent liquidity depletion risk
As reported in recent financial data, SNTI trades at a price-to-sales ratio of 1534.50, a figure that underscores the market's speculative pricing of the firm's proprietary gene circuit platform rather than any near-term expectation of commercial revenue generation or traditional fundamental valuation metrics.
The astronomical P/S multiple suggests that investors are pricing the company as a binary option on the success of its clinical-stage logic-gate technology. This valuation appears disconnected from standard biotech benchmarks, implying that the market is heavily discounting the high probability of future equity dilution required to sustain operations.
Based on the company's reported figures, the ROIC has trended toward -55.9% in 2026Q1, indicating that the firm is currently destroying shareholder capital at an accelerating rate as it funds intensive clinical development programs without a corresponding increase in productive asset returns.
The persistent decline in ROIC reflects the structural challenge of maintaining a high-cost R&D platform while failing to achieve commercial scale. Investors should monitor whether the transition to clinical-stage testing can eventually stabilize these returns, though current trends suggest a continued reliance on external capital to offset operational losses.
According to recent quarterly filings, SNTI's current ratio has compressed to 1.04, reflecting a precarious liquidity position where the company's cash reserves are barely sufficient to cover its immediate short-term obligations as it navigates the expensive Phase 1 clinical trial phase for its lead assets.
This narrow liquidity margin leaves the company with virtually no room for operational error or unexpected clinical delays. The rapid contraction from historical highs suggests that the firm is approaching a critical inflection point where additional financing will be necessary to avoid a liquidity crisis.
As indicated by the company's financial statements, the price-to-book ratio of 43.85 is a fundamentally misleading metric for SNTI, as it fails to capture the value of the firm's intangible intellectual property and proprietary gene circuit architecture which are not adequately reflected on the balance sheet.
Relying on book value for a pre-revenue synthetic biology firm obscures the true economic value of its R&D pipeline. Analysts should instead focus on the cash runway and the probability-weighted net present value of clinical milestones, as book value is essentially a legacy accounting artifact in this business model.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNTI stock.
Senti Biosciences, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Senti Biosciences, Inc.'s return on equity (ROE) is -393.4%. The historical average is -152.1%.
Based on historical data, Senti Biosciences, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Senti Biosciences, Inc. has -16431.8% gross margin and -289668.2% operating margin.